Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
COLL

COLL - Collegium Pharmaceutical Inc Stock Price, Fair Value and News

$44.79-0.53 (-1.17%)
Market Closed

66/100

COLL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

66/100

COLL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$54.1

Target 3M

$47.5

Target 6M

$49.6

COLL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

COLL Price Action

Last 7 days

-4.7%

Last 30 days

-9.5%

Last 90 days

25.6%

Trailing 12 Months

36.7%

COLL RSI Chart

COLL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

COLL Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

24.23

Price/Sales (Trailing)

1.87

EV/EBITDA

8.04

Price/Free Cashflow

4.89

COLL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$54.1

Target 3M

$47.5

Target 6M

$49.6

COLL Fundamentals

COLL Revenue

Revenue (TTM)

757.1M

Rev. Growth (Yr)

31.42%

Rev. Growth (Qtr)

11.36%

COLL Earnings

Earnings (TTM)

58.4M

Earnings Growth (Yr)

237.51%

Earnings Growth (Qtr)

162.93%

COLL Profitability

EBT Margin

10.68%

Return on Equity

21.27%

Return on Assets

3.64%

Free Cashflow Yield

20.43%

COLL Investor Care

Buy Backs (1Y)

1.98%

Diluted EPS (TTM)

1.61

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2025664.3M707.0M757.1M0
2024566.9M576.7M599.2M631.4M
2023524.9M536.9M546.6M566.8M
2022272.9M313.5M361.7M463.9M
2021321.2M326.1M325.8M276.9M
2020298.7M301.7M307.9M310.0M
2019291.2M293.2M295.9M296.7M
201890.1M159.6M217.8M280.4M
20174.6M7.4M19.0M28.5M
2016006.8M1.7M
201300012.0M
Get all data in R, Python etc through our Historical Stock Data APIs

About Collegium Pharmaceutical Inc

COLL
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
 CEO
 WEBSITEcollegiumpharma.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES207

Collegium Pharmaceutical Inc Frequently Asked Questions

COLL is the stock ticker symbol of Collegium Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Collegium Pharmaceutical Inc is 1.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check COLL's fair value in chart for subscribers.

The fair value guage provides a quick view whether COLL is over valued or under valued. Whether Collegium Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Collegium Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COLL.

As of Wed Jan 28 2026, COLL's PE ratio (Price to Earnings) is 24.23 and Price to Sales (PS) ratio is 1.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COLL PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Collegium Pharmaceutical Inc has provided 0.102 (multiply by 100 for percentage) rate of return.